FDA seeks White House approval for policy easing access to unproven peptides
The agency plans to grant enforcement discretion for peptide drugs despite internal scientific warnings about safety and efficacy risks.
Key points
- The FDA submitted an Interim Access Policy for White House review to allow enforcement discretion on certain peptides.
- Internal scientists determined that popular peptide injections lack data on safety and efficacy and pose health risks.
- An advisory panel with ties to peptide businesses recommended reversing previous restrictions on six of seven reviewed drugs.
The Food and Drug Administration has submitted a proposed interim policy to the White House that would ease restrictions on unproven peptide drugs. According to a filing notice on the Office of Management and Budget website, the agency is seeking approval to grant enforcement discretion on these substances. This move aligns with Health Secretary Robert F. Kennedy Jr.’s stated goal of ending regulatory barriers, despite scientific objections regarding patient safety.
People familiar with the proposal told the Associated Press that the policy would allow the FDA to choose not to enforce current restrictions. This assurance is intended for specialty compounding pharmacies that wish to manufacture these drugs. The Department of Health and Human Services did not respond to a request for comment from Ars Technica regarding the specific details or timeline of this regulatory shift.
Regulatory Reversal and Scientific Concerns
In 2023, FDA scientists determined that a dozen popular injectable peptides lacked sufficient data to prove safety or efficacy. Consequently, the agency removed these substances from the list of drugs that compounding pharmacies are permitted to create. The scientific staff concluded that the peptides posed significant risks without verified medical benefits, leading to their initial restriction.
Despite these findings, the popularity of these unproven injections has grown. Sellers continue to market the drugs with unsupported claims about improving appearance, boosting energy, and healing injuries. These products are particularly prevalent among followers of Kennedy’s Make America Healthy Again movement, where many prominent figures actively sell peptide products.
Advisory Panel and Conflict of Interest
In April, the FDA announced it would reconsider the status of twelve unproven peptides. In June, Kennedy appointed nine new members to a thirteen-member advisory panel tasked with reviewing these substances. At least six of the new appointees have direct ties to peptide-related businesses and clinics, raising concerns about potential conflicts of interest within the review process.
During a July meeting, this panel voted to recommend adding six of the first seven peptides back to the allowable list for compounding pharmacies. These recommendations directly overruled FDA staff scientists who maintained that the drugs still lack necessary safety and efficacy data. The agency is now moving forward with plans to formalize this access despite the ongoing scientific dissent.
What should you do?
Security and technology professionals monitoring health-sector regulatory changes should track official Federal Register notices for finalized policy language. Organizations handling health data should prepare for potential shifts in compliance requirements related to compounding pharmacies. Monitor official FDA communications for any updates on the Interim Access Policy status.
What to do and how to stay safe: FDA
- Monitor official Federal Register postings for finalized language on the Interim Access Policy.
- Review internal compliance guidelines to identify any exposure to compounding pharmacy supply chains.
- Watch for official FDA statements confirming or denying the enforcement discretion measures.
- Consult legal counsel regarding potential liability changes if your organization distributes or tracks these drugs.
Step-by-step guide: Mobile Device Security: How to Protect Data Beyond Passwords
General security guidance from the Threat Times newsroom. It is not confirmed advice from the organisations named in this story.
Frequently asked questions
What is the Interim Access Policy for peptides?
It is a proposed FDA policy seeking White House approval to grant enforcement discretion, allowing the agency to not enforce current restrictions on certain peptide drugs.
Did FDA scientists support the use of these peptides?
No, FDA staff scientists determined in 2023 that the peptides lacked data on safety and efficacy and posed risks, leading to their initial removal from the compounding list.
Who serves on the advisory panel reviewing these drugs?
The panel includes nine new members appointed by Robert F. Kennedy Jr., at least six of whom have ties to peptide-related businesses and clinics.
